Abstract
1,3,5-Triazine-based compounds form a privileged class of compounds in the medicinal chemistry field as they are versatile synthetic scaffolds possessing wide spectra of biological effects including potential anticancer activity. 1,3,5-Triazine compounds explored for anticancer activities have been reported to act by various mechanisms on several molecular targets in human cells such as methyltransferase (DNMT), heat shock protein 90 (Hsp90) and phosphoinositide 3-kinase (PI3K). This review focuses on the synthetic strategies for current developments of 1,3,5-triazine-based anticancer agents and discuses the docking studies that confirm their unique binding modes in the targeted receptors active sites. This article also aims to highlight the future directions for the easy access to these frameworks of more potent and specific anticancer activity.
Keywords: Anticancer, enzymes, molecular docking, synthetic methods, 1, 3, 5-triazines, anti-protozoals.
Graphical Abstract
Mini-Reviews in Medicinal Chemistry
Title:Development, Potential Anticancer Activity and the Receptor Profile of Different Functionalized 1,3,5-Triazine Derivatives
Volume: 18 Issue: 15
Author(s): Mona O. Sarhan, Mohamed A. Motaleb, Ismail T. Ibrahim, Manal M. Anwar* Wafaa. A. Zaghary*
Affiliation:
- Department of Therapeutical Chemistry, National Research Centre, Dokki, Cairo 12622,Egypt
- Department of Pharmaceutical Chemistry, College of Pharmacy, Helwan University, Cairo 11795,Egypt
Keywords: Anticancer, enzymes, molecular docking, synthetic methods, 1, 3, 5-triazines, anti-protozoals.
Abstract: 1,3,5-Triazine-based compounds form a privileged class of compounds in the medicinal chemistry field as they are versatile synthetic scaffolds possessing wide spectra of biological effects including potential anticancer activity. 1,3,5-Triazine compounds explored for anticancer activities have been reported to act by various mechanisms on several molecular targets in human cells such as methyltransferase (DNMT), heat shock protein 90 (Hsp90) and phosphoinositide 3-kinase (PI3K). This review focuses on the synthetic strategies for current developments of 1,3,5-triazine-based anticancer agents and discuses the docking studies that confirm their unique binding modes in the targeted receptors active sites. This article also aims to highlight the future directions for the easy access to these frameworks of more potent and specific anticancer activity.
Export Options
About this article
Cite this article as:
Sarhan O. Mona , Motaleb A. Mohamed, Ibrahim T. Ismail , Anwar M. Manal *, Zaghary A. Wafaa. *, Development, Potential Anticancer Activity and the Receptor Profile of Different Functionalized 1,3,5-Triazine Derivatives, Mini-Reviews in Medicinal Chemistry 2018; 18 (15) . https://dx.doi.org/10.2174/1389557517666170927160256
DOI https://dx.doi.org/10.2174/1389557517666170927160256 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
LHON: Mitochondrial Mutations and More
Current Genomics Recent Patents on Devices and Technologies for Early Cancer Diagnostics
Recent Patents on Biomedical Engineering (Discontinued) Peripheral Neuropathy Induced by Paclitaxel: Recent Insights and Future Perspectives
Current Neuropharmacology CYP1A2, CYP2A6, CYP2B6, CYP3A4 and CYP3A5 Polymorphisms in Two Bantu-Speaking Populations from Cameroon and South Africa: Implications for Global Pharmacogenetics
Current Pharmacogenomics and Personalized Medicine Targeting Trail Towards the Clinic
Current Drug Targets Molecular Classification and Drug Response Prediction in Cancer
Current Drug Targets Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance
Current Drug Targets Hydroxysteroid Dehydrogenase (17β -HSD3, 17β-HSD5, and 3α-HSD3) Inhibitors:Extragonadal Regulation of Intracellular Sex Steroid Hormone Levels
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Multimodality Imaging of CXCR4 in Cancer: Current Status towards Clinical Translation
Current Molecular Medicine Lipases in Medicine: An Overview
Mini-Reviews in Medicinal Chemistry Peptides for Tumour Therapy and Diagnosis: Current Status and Future Directions
Current Medicinal Chemistry Insights into Ecto-5’-Nucleotidase as a New Target for Cancer Therapy: A Medicinal Chemistry Study
Current Medicinal Chemistry Molecular and Clinical Analysis of Predictive Biomarkers in Non-Small-Cell Lung Cancer
Current Medicinal Chemistry Pharmacological Inhibitors of NAD Biosynthesis as Potential An ticancer Agents
Recent Patents on Anti-Cancer Drug Discovery Barminomycin, a Model for the Development of New Anthracyclines
Anti-Cancer Agents in Medicinal Chemistry Angiogenesis and Anti-angiogenic Therapies in Epithelial Ovarian Cancer
Current Angiogenesis (Discontinued) Cationic Liposome Mediated Delivery of FUS1 and hIL-12 Coexpression Plasmid Demonstrates Enhanced Activity against Human Lung Cancer
Current Cancer Drug Targets Synergistic Approaches to Clinical Oncology Biomarker Discovery
Current Topics in Medicinal Chemistry Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors
Clinical Cancer Drugs Cytokine Network: New Targeted Therapy for Pancreatic Cancer
Current Pharmaceutical Design